Navigation Links
A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
Date:9/9/2013

EXTON, Pa., Sept. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in their PatientTrends®: Hepatitis C Virus (US) 2013 report that approximately 40 percent of surveyed treatment-naive hepatitis C virus (HCV) patients and half of the prior treatment failure patients plan to receive an HCV antiviral regimen within the next year. However, the majority of these respondents did not know which regimen they will be initiating and only 9 and 14 percent, respectively, indicated they are planning to receive a treatment other than a currently-available regimen. Further, almost 40 percent of surveyed HCV patients also reported that their physician has previously recommended delaying treatment until new regimens become available and findings suggest that many patients are willing wait for safer and more effective regimens, especially if their liver disease is not advanced. The study also finds that awareness of therapies in development among HCV patients is low. Despite over two-thirds of the respondents indicating discussing products in development with their physician, more than three-quarters of the patients lacked unaided awareness of any emerging HCV products.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

"While most treatment-naive and prior treatment failure HCV patients who do not plan to be treated in the next year cite the future availability of better therapies as a reason, many of these patients specifically indicated waiting for interferon-free regimens to become available," said Infectious Diseases Therapy Leader Mladen Tomich, Ph.D. "However, patients overall prioritized effects on liver damage progression and reversal, and achieving sustained virologic response as the most important attributes in an HCV regimen, while exclusion of interferon or ribavirin was perceived as least important. Our research reveals that most HCV patients are prepared to endure a certain level of temporary disability as long as the treatment is efficacious."

Of note, surveyed treatment-naive HCV patients overall believe they have more influence on the management and treatment of their infection than their treating physicians. Also, the level of perceived personal influence over treatment decisions is significantly higher among surveyed treatment-naive patients than among treatment-experienced patients.

PatientTrends®: Hepatitis C Virus (US) 2013 is an annual report that includes data from 245 chronically-infected HCV patients and provides insight into patient demographics, patient-physician relationship, treatment history and plans to initiate treatment. The report also investigates the importance of drug attributes to patients, satisfaction with currently-available HCV therapies and awareness of emerging therapies, including AbbVie's ABT-267, ABT-333 and ABT-450, Boehringer Ingelheim's deleobuvir and faldaprevir, Bristol-Myers Squibb's asunaprevir and daclatasvir, Janssen/Medivir's simeprevir and Gilead's sofosbuvir and ledipasvir.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
3. "AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
4. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
5. South Carolinas Stop-Sale System Achieves Significant Results In Battle Against Meth
6. Tennessee Stop-Sale System Achieves Significant Results In Battle Against Meth
7. Indianas Stop-Sale System Achieves Significant Results In Battle Against Meth
8. Alabamas Stop-Sale System Achieves Significant Results In Battle Against Meth
9. Missouri Stop-Sale System Achieves Significant Results In Battle Against Meth
10. Kansas Stop-Sale System Achieves Significant Results In Battle Against Meth
11. Illinois Stop-Sale System Achieves Significant Results In Battle Against Meth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb 27, 2017 The Dutch ... NATO for use at the security level RESTRICTED. The solution ... NATO organization for the communication of classified information. ... Sectra and Samsung ... an eavesdrop-secure smartphone solution. Sectra Tiger/R is developed by Sectra ...
(Date:2/24/2017)... , February 24, 2017 Following ... Israel , s AMAR is ... $ 250 M w ound care market in ... s BST for inclusion in the National ... reimbursement system   E-QURE Corp. (OTCQB: EQUR), ...
(Date:2/24/2017)... , Feb. 24, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the Cowen and ... the Boston Marriott Copley Place on Tuesday, March 7, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 27, 2017 , ... Orange County ... a chronic inflammatory gum condition that occurs when the bacteria in plaque infect the ... referred to as a scaling and root planing or SRP, and can include surgical ...
(Date:2/27/2017)... China (PRWEB) , ... February 26, 2017 , ... Miro ... This pioneer sound and video system brings songs, movies, TV shows and much more ... sound offers clear, high-definition sound. An immersive view of 1280 x 720 provides crisp ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... 2014. The company had 800 customers and 2,250 RCEs at the time of ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... hair transplantation therapy, is proud to announce a new informational post on robotic ... procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
Breaking Medicine News(10 mins):